IL-5

IL-5

IL-5 Molekülinformation

Molecule Name
Interleukin-5
Molekülalias
IL-5,TRF,IL5,Interleukin-5
Drug Development Progress
Anzahl der klinischen Arzneimittel6
Anzahl der inverkehr gebrachten Arzneimittel3
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
T-cell replacing factor,IL5,Interleukin 5,Eosinophil Differentiation Factor,Colony-Stimulating Factor, Eosinophil,B-Cell Differentiation Factor I,Interleukin-5,IL-5,TRF,Interleukin 5 (Colony-Stimulating Factor, Eosinophil),B Cell Differentiation Factor I,EDF
Molekülhintergrund
Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.

IL-5 Produktliste

Species
  • Human(3)
  • Canine(1)
  • Cynomolgus(1)
  • Mouse(1)
  • Rabbit(1)
  • Rat(1)
Tag
  • His Tag(6)
  • His Tag & Avi Tag(1)
  • Tag Free(1)
Host
  • HEK293(8)
Conjugate
  • Unconjugated(7)
  • Biotin-labeled(1)
Grade
  • RUO(7)
  • PG (pre-GMP)(1)
Low Endotoxin
  • Yes(2)
  • No(6)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
IL-5
Rabbit IL-5 Protein, His Tag
Rabbit
HEK293
SDS-PAGE
ELISA

$360.00

50ug
IL-5
HOTAvitag
IL5-H82Q5
Biotinylated Human IL-5 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLI

$430.00

25ug
IL-5
Cynomolgus IL-5 Protein, His Tag, low endotoxin
Cynomolgus
HEK293
SDS-PAGE
ELISA

$360.00

50ug
IL-5
Human IL-5 Protein, His Tag (Mass Spec verified)
Human
HEK293
SDS-PAGE
ELISABLICELL BASE

$360.00

50ug
IL-5
Canine IL-5 Protein, His Tag (MALS verified)
Canine
HEK293
MALSSDS-PAGE
ELISA

$360.00

50ug
IL-5
Human IL-5 Protein, premium grade
Human
HEK293
MALSSDS-PAGE
ELISACELL BASE

$505.00

50ug
IL-5
Mouse IL-5 Protein, His Tag, low endotoxin (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISASPR

$360.00

50ug
IL-5
Rat IL-5 Protein, His Tag (MALS verified)
Rat
HEK293
MALSSDS-PAGE
ELISA

$360.00

50ug
You Have Viewed 1-8 Of 8 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian)610; SSGJ-610Phase 3 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Asthma; Autoimmune Diseases
Details
SHR-1703SHR-1703Phase 3 ClinicalJiangsu Hengrui Medicine Co Ltd
Asthma; Eosinophilic Asthma; Eosinophilic Granulomatosis With Polyangiitis
Details
RC-1416RC14/16; RC-1416Phase 2 ClinicalNanjing RegeneCore Biotech Co Ltd
Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive
Details
long-acting anti-IL-5 mAb (GSK)Phase 1 ClinicalGlaxosmithkline Plc
Asthma
Details
Mepolizumab biosimilar(Bio Thera Solutions)BAT2606; BAT-2606Phase 1 ClinicalBio-Thera Solutions Ltd
Asthma; Autoimmune Diseases; Nasal Polyps; Sinusitis
Details
Mepolizumab biosimilar (CTTQ Pharma)TQC-3566; TQC3566Phase 1 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Lymphohistiocytosis, Hemophagocytic; Nasal Polyps; Sinusitis; Vasculitis
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
ReslizumabCEP-38072; SCH-5570; TRFK-5; SCH-55700; CDP-835; CTx-55700ApprovedTeva Pharmaceutical Industries LtdCinquil, Cinqair, CinqaeroUnited StatesAsthmaTeva Respiratory Llc2016-03-23
Asthma; Bronchitis; Eosinophilic Esophagitis; Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia
Details
DepemokimabGSK-3511294; AQ82742999; GSK3511294; GSK-294; GSK294ApprovedGlaxosmithkline Plc易适来, ExdensurUnited KingdomAsthma; Sinusitis; Nasal PolypsGlaxosmithkline Plc2025-12-15
Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Eosinophilic Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Vasculitis
Details
MepolizumabSB-240563; 240563ApprovedGlaxosmithkline PlcBosatria, Nucala, 美泊利珠单抗, 新可来United StatesAsthmaGlaxosmithkline Llc2015-11-04
Angioedema; Asthma; Bronchitis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilia; Eosinophilic Esophagitis; Eosinophilic Granulomatosis With Polyangiitis; Fasciitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Virus Diseases
Details
Customer Reviews